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Simian varicella virus (SVV) DNA was detected in blood mononuclear cells (MNCs) of adult African green monkeys 7 days
to 23 months after intratracheal inoculation with 103 plaque forming units. Infectious virus was not detected in MNCs at 14
months postinfection (p.i.), and electron microscopic (EM) analysis of MNCs from two monkeys 21 months p.i. did not reveal
virus particles. Real-time quantitative PCR analysis of DNA from blood MNCs taken at multiple intervals from SVV-infected
monkeys M7 and M8 revealed a 10- to 100-fold decrease, but not clearance of SVV DNA in MNCs between 11 and 17 months
p.i. Thereafter, the SVV DNA copy number did not decrease further between 17 and 23 months p.i. PCR analysis of MNCs
sorted by flow cytometry revealed SVV DNA in T cells (CD4, CD8) and B cells (CD20), but not in monocyte-macrophages
(CD14), 10 days p.i. At 11 and 23 months p.i., SVV DNA was found exclusively in CD4 and CD8 T cells. Whether the
detection of SVV DNA in CD4 and CD8 MNCs many months after the resolution of acute varicella reflects continued
infection of these cells that began at the time of acute varicella or represents infection acquired by MNCs trafficking throughINTRODUCTION
Simian varicella virus (SVV) causes chickenpox in
monkeys (Padovan and Cantrell, 1986; Soike et al., 1984).
The clinical (Padovan and Cantrell, 1986), pathological
(Dueland et al., 1992), and virologic (Clarke et al., 1992;
Gray et al., 1992) features of SVV infection are similar to
those of human varicella, and both varicella zoster virus
(VZV) and SVV become latent in ganglia at multiple levels
of the neuraxis (Mahalingam et al., 1990, 1991, 1992). As
in VZV infection, viremia occurs during SVV infection of
nonhuman primates (Wenner et al., 1977). SVV DNA can
be detected in blood mononuclear cells (MNCs) of mon-
keys for 2 months after intratracheal inoculation; in these
same monkeys, SVV infects ganglia before the appear-
ance of rash, indicating the importance of viremia in the
pathogenesis of varicella (Mahalingam et al., 2001).
Viremia occurs in varicella (Ozaki et al., 1994), zoster
(Gilden et al., 1987, 1988; Vafai et al., 1988), postherpetic
neuralgia (PHN) (Gilden et al., 1988; Mahalingam et al.,
1995; Vafai et al., 1988), zoster sine herpete (Gilden et al.,
1994), and in individuals in whom virus reactivates sub-
clinically (Gilden et al., 1992). VZV can be isolated from
lymphocytes and macrophages (Asano et al., 1990), and
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192viral proteins are detectable in T cells, B cells, and
monocytes of varicella patients (Mainka et al., 1998). In
vitro studies have revealed limited VZV replication in T
cells, although B cells, monocytes, and macrophages are
also permissive (Arbeit et al., 1982; Koropchak et al.,
1989; Soong et al., 2000; Zerboni et al., 2000).
VZV DNA has been detected by in situ hybridization in
human blood MNCs 56 days after acute varicella and 36
days after zoster (Gilden et al., 1988). Using PCR, Mainka
et al. (1998) detected VZV DNA in human MNCs 7 days
after varicella and 6 days after zoster. Vonsover and
co-workers (1987) detected VZV DNA at multiple intervals
in MNCs up to 197 days after onset of varicella by
dot-blot hybridization. VZV DNA is present in CD4 and
CD8 T cell, B cell, and monocyte/macrophage subpopu-
lations during acute varicella (Ito et al., 2001), but the
exact MNC subpopulation(s) important for viremia during
varicella and after VZV reactivation has remained un-
clear. We describe here our analysis of blood MNCs and
their subpopulations from African green monkeys inoc-
ulated intratracheally with SVV and examined for months
to years after primary infection for the presence of SVV
DNA.
RESULTS
Detection of SVV DNA in monkey blood MNCsinfected tissues is unknown. © 2002 Elsevier Science (USA)
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genome (ORFs 4, 21, 40, 63, and 67; Fig. 1A) was detected
in blood MNCs of SVV-infected monkeys M1 (7 days
postinfection, p.i.), M3–M5 (10 months p.i.) (Fig. 1B), and
M6 (12 months p.i.) (data not shown). SVV DNA was not
detected in uninfected BSC-1 DNA. SVV ORF 21 specific
DNA was detected in blood MNCs of SVV-infected mon-
keys at 11 months p.i. (M7 and M8), but not in an unin-
fected monkey; actin was detected in all SVV-negative
DNA samples (Fig. 1C).
Detection of SVV DNA in blood MNCs by real-time
quantitative PCR
The SVV DNA copy number in blood MNC samples
taken at 11, 17, and 23 months from SVV-infected mon-
keys M7 and M8 was determined by real-time quantita-
tive PCR amplification of SVV ORF 21 DNA (Table 1). The
average SVV copy number from duplicate samples was
normalized to 100 ng of -actin DNA. Monkey M7 had
338, 7, and 13 copies of SVV ORF 21 DNA per 100 ng of
-actin DNA at 11, 17, and 23 months, respectively. Mon-
key M8 had 86, 11, and 8 copies of SVV ORF 21 DNA per
100 ng of -actin DNA at 11, 17, and 23 months, respec-
tively.
Detection of SVV DNA in blood MNC subpopulations
Nested PCR analyses (Fig. 2A) revealed SVV ORFs 21
and 63 specific sequences in DNA from CD4, CD8,
and total blood MNCs of one monkey (M2) at 10 days p.i.
Only SVV ORF 63 specific sequences were detected in
DNA from CD20 cells, and neither SVV ORF 21 nor 63
was detected in CD14 cells. In two other monkeys (M7
and M8), nested PCR at 14 months p.i. detected SVV
ORFs 21 and 63 specific sequences in DNA from CD4
cells and total blood MNCs, but not in DNA from CD14
or CD20 cells (Fig. 2B). SVV DNA sequences were not
detected in DNA from CD4, CD14, or CD20 cells or
from unsorted MNCs of an uninfected monkey. At 23
months p.i., SVV ORF 63 specific DNA was detected in
DNA from CD4 and CD8 cells and from unsorted blood
MNCs from monkeys M7 and M8 (Fig. 2C). Actin was
detected in all DNA samples examined.
Absence of infectious SVV in blood MNCs
An SVV-induced cytopathic effect (CPE) was observed
in Vero cells cocultivated with blood MNCs harvested
from monkeys M7 and M8 during acute varicella (viremia
in Table 2), but not at 14 months p.i. (not shown). Neither
SVV ORF 21 nor 63 specific sequences were detected in
DNA extracted from Vero cells subcultivated three times
after cocultivation with MNCs harvested at 14 months p.i.
(Fig. 3). Actin-specific sequences were detected in each
sample. Electron microscopic (EM) analysis of MNCs
from two monkeys (M7 and M8) 21 months p.i. did not
reveal virus particles (data not shown).
DISCUSSION
SVV infection of African green monkeys causes a dis-
seminated and often fatal disease characterized by cell-
TABLE 1
SVV DNA Copy Number in Blood MNCs from Adult African Green
Monkeys Experimentally Infected Intratracheally with SVV
Monkey
SVV DNA copy number/100 ng
of -actin
Time p.i. (months)
11 17 23
M7 338 7 13
M8 86 11 8
FIG. 1. Detection of multiple regions of the SVV genome in MNCs
from adult African green monkeys inoculated intratracheally with 103
PFU of SVV. (A) Location of SVV ORFs 4, 21, 40, 63, and 67 on the SVV
genome. The unique long (UL), unique short (US), and the inverted
repeat (IRS and TRS) sequences are also indicated. (B) Presence of SVV
ORF 4, 21, 40, 63, and 67 specific DNA sequences in blood MNCs from
SVV-infected monkeys at 7 days (M1) and 10 months (M3–M5) p.i. (C)
Presence of SVV ORF 21 specific DNA in blood MNCs of SVV-infected
monkeys at 7 days (M1) and 11 months p.i. (M7 and M8). DNA from
MNCs of an uninfected monkey and from BSC-1 cells did not reveal this
sequence. Actin was detected in all SVV-DNA-negative samples. Blood
MNC DNA was prepared as described under Materials and Methods.
SVV DNA was detected using nested PCR followed by Southern blot
hybridization of amplified products to oligonucleotides specific for each
SVV ORF.
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associated viremia and vesicular skin lesions. Infectious
SVV has been detected in peripheral blood MNCs of
African green monkeys up to 11 days after experimental
intratracheal inoculation (Soike et al., 1984, 1986), and
we have previously demonstrated the presence of SVV-
specific DNA in MNCs from intratracheally infected mon-
keys up to 2 months p.i. (Mahalingam et al., 2001).
Herein, we expanded our analysis by examining total
MNCs and several subpopulations from SVV-infected
monkeys for up to 2 years after intratracheal inoculation
for the presence of SVV DNA sequences representing
multiple regions of the viral genome. To study as many
animals as possible virologically (while recognizing that
statistical significance could not be achieved), we in-
cluded six monkeys that were treated with short courses
of antiviral agents (Table 2) as part of different studies
unrelated to the pathogenesis of SVV. In fact, none of the
short antiviral treatments affected the detection of SVV
DNA in blood MNCs. It is possible that a higher dose or
longer course of treatment with famciclovir would have
resulted in clearance of SVV from blood MNCs.
SVV DNA sequences corresponding to ORFs 4, 21, 40,
63, and 67 were detected by PCR in blood MNCs from all
monkeys sacrificed 7 days, 10 months (Fig. 1), and 12
months p.i. All four SVV-infected monkeys sacrificed 10
or 12 months p.i. developed viremia during acute vari-
cella (Table 2). Although the detection of SVV DNA in
blood MNCs during acute varicella (7 days p.i.) was
expected, its detection at 10 and 12 months p.i. was not.
SVV ORFs 4, 21, 40, 63, and 67 span the SVV genome,
FIG. 2. Detection of SVV ORF 21 and SVV ORF 63 specific DNA in peripheral blood MNC subpopulations of adult African green monkeys (A) 10 days
(M2), (B) 14 months (M7, M8), and (C) 23 months (M7, M8) after intratracheal inoculation with 103 PFU of SVV. MNCs from SVV-infected monkeys M2,
M7, and M8 and an uninfected monkey were sorted by flow cytometry using anti-CD4, anti-CD8, anti-CD14, and anti-CD20 monoclonal antibodies as
described under Materials and Methods. Total MNC DNA from the acutely infected monkey (M1) was used as a positive control for PCR. DNA
extracted from the MNC populations was analyzed by nested PCR followed by Southern blot hybridization as described under Materials and Methods.
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and detection of all five SVV DNA sequences suggests
that most if not all of the virus genome is present. De-
tection of SVV DNA in MNCs months after intratracheal
inoculation might reflect infection of MNCs during traf-
ficking through tissue. We have previously shown that
SVV continues to be transcribed in trigeminal and dorsal
root ganglia as well as in liver and lung of monkeys
months after intratracheal inoculation with SVV (White et
al., 2002).
Two of the SVV-infected monkeys (M7 and M8) were
studied at multiple intervals before sacrifice 2 years p.i.
Blood samples analyzed 11 months p.i. revealed the
presence of SVV DNA sequences (Fig. 1C). PCR analysis
of MNCs from blood obtained 14 months p.i. and sorted
by flow cytometry using anti-CD4 (T cell marker), anti-
CD14 (monocyte/macrophage marker), and anti-CD20 (B
cell marker) monoclonal antibodies identified SVV-spe-
cific DNA in CD4, but not in CD14 or CD20 cells (Fig.
2B). MNCs obtained 23 months p.i. from the same two
monkeys and sorted using anti-CD4 and anti-CD8 mono-
clonal antibodies also contained SVV-specific se-
quences (Fig. 3). Interestingly, SVV-specific DNA was
detected in CD20 cells in addition to CD4 and CD8
cells of an acutely infected monkey (M2) (Fig. 2A). In the
CD20 population, SVV DNA was detected using one of
the primer pairs (ORF 63) but not the other (ORF 21),
perhaps reflecting a difference in sensitivity between the
two primer sets. Taken together, our data indicate that
SVV infects both T and B cells during acute varicella, but
after resolution of the primary infection, virus is cleared
from B cells and remains in T cells. However, it is not
clear whether the detection of SVV DNA in CD4 and
CD8 MNCs many months after the resolution of acute
varicella reflects continued infection of these cells that
began at the time of acute varicella or represents infec-
tion acquired by MNCs trafficking through infected tis-
sues. The latter seems more likely since multiple SVV-
specific transcripts can be detected in ganglia, liver, and
lung months after intratracheal infection (White et al.,
2002). Even though nervous system tissue is considered
immune-privileged, activated T cells can traffic through
these tissues randomly, regardless of their antigen spec-
ificity (Hickey et al., 1991). Thus, it is possible that CD4
and CD8 cells could become infected while trafficking
through ganglia.
TABLE 2
Viremia and Rash in Adult African Green Monkeys Experimentally Infected Intratracheally with SVV
Monkey
Sacrificed
(time p.i.)
Inoculum
(PFU) Antiviral Viremiaa Rashb
M1 7 days 4.5 103 No Positivec /
M2 Alive 2.2 103 No 200 PFU 4
M3 10 months 4.0 103 Yesd TNTCe 2
M4 10 months 4.0 103 Yesd 285 PFU 3
M5 10 months 4.0 103 Yes f 945 PFU 3
M6 12 months 4.0 103 Yesg 1550 PFU 2
M7 24 months 4.0 103 Yes f Positivec 4
M8 24 months 4.0 103 Yesg Positivec 2
a Viremia was determined on blood sample obtained 6 days p.i.
b Severity determined by Dr. K. Soike (Tulane National Primate Research Center) based on extent of rash and hemorrhagic vesicles at peak of acute
disease 10–12 days after SVV inoculation.
c Virus cultured from blood; plaque forming units (PFU) unknown.
d 100 mg of famciclovir daily for 7 days, at 3 months and 4 months p.i.
e TNTC, plaques too numerous to count.
f 20 mg of experimental antiviral drug (Wyeth-Ayerst, Radnor, PA) twice a day for 10 days (started 48 h p.i.) and 100 mg of famciclovir daily for 7 days,
at 3 months and 4 months p.i.
g 40 mg of Wyeth antiviral drug twice a day for 10 days (started 48 h p.i.) and 100 mg of famciclovir daily for 7 days at 3 months and 4 months p.i.
FIG. 3. Absence of SVV ORF 21 and 63 specific DNA in Vero cells
cocultivated with blood MNCs from an uninfected monkey and SVV-
infected monkeys (M7 and M8) at 14 months after intratracheal inocu-
lation with 103 PFU of SVV. After cocultivation with blood MNCs, Vero
cells were subcultivated three times before DNA extraction. Actin and
SVV DNA were detected using nested PCR followed by Southern blot
hybridization as described under Materials and Methods.
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Real-time quantitative PCR analysis of DNA from blood
MNCs taken at multiple intervals from SVV-infected mon-
keys M7 and M8 revealed a 10- to 100-fold decrease, but
not clearance of SVV DNA in MNCs between 11 and 17
months p.i. Thereafter, the SVV DNA copy number did not
decrease further between 17 and 23 months p.i. We were
unable to obtain blood samples from SVV-infected mon-
keys M7 and M8 during acute infection; therefore, com-
parisons to the SVV DNA copy number during acute
varicella could not be made. The decline in SVV DNA
copy number between 11 and 17 months p.i. is likely due
to the clearing of the virus following resolution of acute
varicella. The maintenance of the SVV DNA copy number
in blood MNCs between 17 and 23 months may reflect a
chronic persistent infection where the blood MNCs are
continually being infected at very low levels. Alterna-
tively, the SVV-infected blood MNCs present at 17 and 23
months p.i. may be the same cell which has not elimi-
nated the viral DNA nor turned over. Future studies will
include detailed analysis of SVV-infected MNCs to de-
termine if SVV-specific transcripts, proteins, and viral
particles are present.
In vitro attempts by several laboratories to infect
MNCs with VZV have suggested that these cells are only
semipermissive for VZV (Arbeit et al., 1982; Gilden et al.,
1987; Koropchak et al., 1989; Soong et al., 2000; Zerboni
et al., 2000). Although VZV-specific DNA and proteins can
be detected in T and B lymphocytes, monocytes, and
macrophages, infectious VZV is recovered primarily from
T lymphocytes (Arbeit et al., 1982; Koropchak et al., 1989;
Soong et al., 2000). We examined blood obtained at 14
months p.i. for the presence of infectious SVV by cocul-
tivation with a permissive cell line; although no CPE
developed and SVV DNA was not detected in cultures
after three blind passages (Fig. 3), we cannot rule out
inefficient or abortive SVV infection. An attempt to detect
virus particles by EM in SVV-infected mononuclear cells
was made at 21 months p.i. Although no virus particles
were observed, we cannot conclusively state that they
are not present.
Subclinical VZV viremia due to reactivation develops in
bone marrow transplant recipients (Ljungman et al.,
1986; Wilson et al., 1992), and the presence of VZV DNA
in blood MNCs after resolution of zoster correlates with
postherpetic neuralgia (Gilden et al., 1988; Mahalingam
et al., 1995). Acute varicella and reactivation of VZV in
immunocompromised humans can be fatal and is com-
monly disseminated (Ljungman et al., 1986; Wilson et al.,
1992). Our detection of SVV DNA in MNCs of clinically
normal monkeys up to 2 years after experimental inocu-
lation with 103 plaque forming units (PFU) of SVV com-
bined with the detection of SVV late transcripts in ganglia
from other SVV-infected monkeys up to 1 year p.i. (White
et al., 2002) supports the hypothesis that intratracheal
inoculation leads to a persistent viral infection. Overall,
our experimental SVV inoculation conditions resulted in
virological features similar to those observed in immu-
nocompromised VZV-infected humans as well as some
patients with postherpetic neuralgia and zoster sine her-
pete. Further studies of this model of varicella infection
may help to test the efficacy of antiviral drugs to treat
productive varicella infection.
MATERIALS AND METHODS
Cells and virus
African green monkey kidney cells (BSC-1 and Vero)
were propagated in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum
(DMEM10) at 37°C in 5% CO2. The Delta-herpesvirus
strain of SVV (obtained from K. Soike, Tulane National
Primate Research Center, Covington, LA) was propagated
by cocultivation of uninfected and virus-infected BSC-1
cells at a ratio of 8:1 in DMEM10 at 37°C in 5% CO2. Blood
MNCs of SVV-infected African green monkeys removed 6
days and 14 months after intratracheal inoculation were
cocultivated with Vero cells in DMEM10 at 37°C in 5%
CO2 subcultivated three times and examined for a viral
cytopathic effect. Blood MNCs from two monkeys 21
months p.i. were prepared for electron microscopic exam-
ination as previously described for virus-infected cells in
culture (Mahalingam et al., 1998).
Experimental inoculation of African green monkeys
Adult African green monkeys (M1–M8) were inocu-
lated intratracheally with 103–104 PFU of SVV. Table 2
summarizes dose, antiviral treatment, and severity of
rash and viremia in adult African green monkeys (M1–
M8) inoculated intratracheally with SVV. Viremia devel-
oped 4–6 days p.i. and rash developed 7–11 days p.i.
Viremia was detected by cocultivation of blood MNCs
with Vero cells on days 4, 5, or 6 p.i. Blood was obtained
at the time of sacrifice for monkeys M1 and M3–M6, at 10
days p.i. for monkey M2, and at 11, 14, and 23 months for
monkeys M7 and M8. MNCs were prepared from each
blood sample as described below. Monkey M1 and M2
received no antiviral treatment. Monkeys M3–M8 re-
ceived 100 mg of famciclovir daily for 7 days, at 3 months
and 4 months p.i. In addition, monkeys M5–M8 were
given 20 or 40 mg of an experimental antiviral drug
(Wyeth-Ayerst, Radnor, PA) twice daily for 10 days start-
ing at 48 h p.i. The experimental drug is a small hydro-
phobic nonnucleoside molecule with an approximate
molecular weight of 500 Da.
Blood MNC preparation
Blood (2–5 ml) was collected in EDTA-coated purple-
top tubes as described (Miller et al., 1988) and centri-
fuged at room temperature for 10 min at 1000 rpm (220 g),
and plasma was removed. Cells were mixed with 5 vol
140 mM NH4Cl:170 mM Tris (pH 7.5), incubated at 37°C
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for 10 min, and centrifuged at room temperature for 5 min
at 2200 rpm (1200 g). The supernatant was discarded
and the procedure repeated until the cell pellet was no
longer red. The cell pellet was resuspended in 4 ml
0.85% NaCl and centrifuged as above. After removal of
the supernatant, the cell pellet was resuspended in 180
l (DNA extraction) or 1 ml (flow cytometry) of phos-
phate-buffered saline (PBS).
Flow cytometry
Blood MNCs from an uninfected monkey and monkeys
M2, M7, and M8 were sorted by flow cytometry at the
University of Colorado Cancer Center Flow Cytometry
Core. MNCs (106–107 cells) prepared from monkey M2 at
10 days p.i. were mixed with 20 l fluorescein isothio-
cyanate (FITC)-conjugated mouse anti-CD4 (Leu3A) and
15 l phycoerythrin (PE)-conjugated mouse anti-human
CD8 (Leu2A) monoclonal antibody (both from Becton–
Dickinson, San Jose, CA), or 15 l allophycocyanin
(APC)-conjugated mouse anti-CD14 and 15 l of R-phy-
coerythrin (R-PE)-conjugated mouse anti-CD20 (both
from Caltag Laboratories, Burlingame, CA), incubated at
room temperature for 15 min, and centrifuged at 2200
rpm (1200 g) for 5 min. Cell pellets were resuspended in
500 l of 1 PBS and sorted by flow cytometry. Blood
MNCs (106–107 cells) prepared from monkeys M7 and
M8 at 14 months p.i. and from an uninfected monkey
were sorted using FITC-conjugated mouse anti-CD4
(Leu3A), APC-conjugated mouse anti-CD14, and R-PE-
conjugated mouse anti-CD20, while blood MNCs pre-
pared from the same monkeys at 23 months p.i. were
sorted using FITC-conjugated mouse anti-human CD4
(Leu3A) and R-PE-conjugated mouse anti-human CD8
(Leu2A) monoclonal antibodies.
DNA extraction
DNA was extracted from total MNCs and from CD4,
CD8, CD14, and CD20 subpopulations using the Qia-
gen DNA mini-blood kit (Santa Clarita, CA). DNA was
extracted from BSC-1 cells, SVV-infected BSC-1 cells,
and Vero cells cocultivated with MNCs from an unin-
fected monkey and SVV-infected monkeys M7 and M8
using the Qiagen DNEasy tissue kit.
PCR amplification of actin and SVV DNA
Oligonucleotide primers were selected based on pub-
lished SVV DNA sequences (Clarke et al., 1993, 1996;
Gray et al., 2001) using DNASIS software (Hitachi Soft-
ware Engineering America Ltd., South San Francisco,
CA). The sequences of the primers used in primary and
nested PCR to amplify actin and SVV ORF 4, 21, 40, and
63 specific sequences and the size of the nested PCR
products have been published (White et al., 2002). SVV
67-specific sequences were amplified using primers
67P1 (5-TGGAACAGTCTATCTTGCAGCA-3) and 67P2
(5-ACTGAATGTGGAGGGTTTTCC-3) in primary PCR,
and primers 67P3 (5-GTTACGTCTGATGTGGATA-3) and
67P4 (5-ACTCAGATCGTTCCCGTTTTTCA-3) in nested
PCR. The sequence of the oligonucleotide probe used to
detect the SVV ORF 67 nested PCR product is 5-ACGT-
TACGCACGAAACAAGAA-3, and the size of the nested
PCR product is 322 bp. Nested PCR conditions and
analysis of the PCR products have been detailed (White
et al., 2002).
Real-time quantitative PCR
Number of copies of SVV ORF 21 DNA in blood MNCs
was determined using real-time quantitative PCR. Blood
MNC DNA was extracted as described above. SVV ORF 21
DNA was amplified using forward-primer SU21PF (5-GA-
CACATCAGCGGTTTGCA-3) and reverse-primer SU21PR
(5-TGCACGCTGTGTTAGAATTCG-3). The TaqMan probe
SU21PRB (5-6FAM-TCCATCCTGAACGATAGGCATGTCATA-
AAGA-TAMRA-3) was purchased from Perkin–Elmer, 5-
labeled with 6-carboxyfluorescein (FAM), and 3-labeled
with 6-carboxy-tetramethylrhodamine (TAMRA). Duplicate
amplification reactions were performed in MicroAmp opti-
cal tubes (PE ABI) in a 50 l mix containing 8% glycerol, 1
TaqMan buffer A (500 mM KCl, 100 mM Tris–HCl, 0.1 M
EDTA, 600 nM passive reference dye ROX, pH 8.3 at room
temperature), 300 M each of dATP, dGTP, dCTP, and 600
M dUTP, 5.5 mM MgCl2, 900 nM forward primer, 300 nM
reverse primer, 200 nM probe, 1.25 U AmpliTaq Gold DNA
polymerase (Perkin–Elmer, Foster City, CA), and the target
DNA. Thermal cycling conditions were as follows: activa-
tion of TaqGold at 95°C for 10 min followed by 40 cycles of
amplification (95°C for 15 s and 60°C for 1 min). Reactions
were monitored in real time using an ABI Prism 7700
sequence detector (Perkin–Elmer Corp./Applied Biosys-
tems). Number of copies of control cellular gene (-actin)
was determined using the standard -actin control re-
agents supplied by ABI.
After amplification, real-time data acquisition and anal-
ysis were performed. Fluorescence data were expressed
as Rn, the normalized reporter signal calculated by di-
viding the amount of reporter signal by the amount of
passive reference signal or DRn, representing the
amount of normalized reporter signal minus the amount
of reporter signal before PCR. The detection threshold
was set above the mean baseline fluorescence deter-
mined from the first 15 cycles. Amplification reactions in
which the fluorescence intensity increased above the
threshold were defined as a positive reaction. Threshold
cycle Ct represented the PCR cycle at which an increase
in reporter fluorescence above a baseline signal can first
be detected. A standard curve was generated using the
fluorescence data from the 10-fold serial dilutions of
cloned SVV ORF 21 DNA. The amount of cellular DNA
(-actin) was also determined. The copy number of SVV
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DNA in each duplicate sample was averaged and nor-
malized to the amount of -actin in each sample.
ACKNOWLEDGMENTS
These studies were supported in part by Public Health Service
Grants AG 06127 and NS 32623. T.W. was supported by NIH Training
Grant NS 07321 in Neurovirology–Molecular Biology. We thank Robert
Lasher for electron microscopic analysis, Uma Pugazhenthi at the
quantitative PCR core located in the Cancer Center at UCHSC for the
determination of SVV DNA copy number, Cathy Allen for preparing the
manuscript, and Marina Hoffman for editorial assistance.
REFERENCES
Arbeit, R. D., Zaia, J. A., Valerio, M. A., and Levin, M. J. (1982). Infection
of human peripheral blood mononuclear cells by varicella-zoster
virus. Intervirology 18, 56–65.
Asano, Y., Itakura, N., Kajita, Y., Suga, S., Yoshikawa, T., Yazaki, T., Ozaki,
T., Yamanishi, K., and Takahashi, M. (1990). Severity of viremia and
clinical findings in children with varicella. J. Infect. Dis. 161, 1095–
1098.
Clarke, P., Brunschwig, A., and Gilden, D. H. (1993). DNA sequence of
a simian varicella virus gene that encodes a homologue of varicella
zoster virus IE62 and herpes simplex virus ICP4. Virology 197, 45–52.
Clarke, P., Matlock, W. L., Beer, T., and Gilden, D. H. (1996). A simian
varicella virus (SVV) homolog to varicella-zoster virus gene 21 is
expressed in monkey ganglia latently infected with SVV. J. Virol. 70,
5711–5715.
Clarke, P., Rabkin, S. D., Inman, M. V., Mahalingam, R., Cohrs, R.,
Wellish, M., and Gilden, D. H. (1992). Molecular analysis of simian
varicella virus DNA. Virology 190, 597–605.
Dueland, A. N., Martin, J. R., Devlin, M. E., Wellish, M., Mahalingam, R.,
Cohrs, R., Soike, K. F., and Gilden, D. H. (1992). Acute simian varicella
infection. Clinical, laboratory, pathologic, and virologic features. Lab.
Invest. 66, 762–773.
Gilden, D. H., Devlin, M., Wellish, M., Mahalingham, R., Huff, C., Hay-
ward, A., and Vafai, A. (1988). Persistence of varicella-zoster virus
DNA in blood mononuclear cells of patients with varicella or zoster.
Virus Genes 2, 299–305.
Gilden, D. H., Dueland, A. N., Devlin, M. E., Mahalingam, R., and Cohrs,
R. (1992). Varicella-zoster virus reactivation without rash. J. Infect.
Dis. 166(Suppl. 1), S30–S34.
Gilden, D. H., Hayward, A. R., Krupp, J., Hunter-Laszlo, M., Huff, J. C., and
Vafai, A. (1987). Varicella-zoster virus infection of human mononu-
clear cells. Virus Res. 7, 117–129.
Gilden, D. H., Wright, R. R., Schneck, S. A., Gwaltney, J. M., and Ma-
halingam, R. (1994). Zoster sine herpete, a clinical variant. Ann.
Neurol. 35, 530–533.
Gray, W. L., Pumphrey, C. Y., Ruyechan, W. T., and Fletcher, T. M. (1992).
The simian varicella virus and varicella zoster virus genomes are
similar in size and structure. Virology 186, 562–572.
Gray, W. L., Starnes, B., White, M. W., and Mahalingam, R. (2001). The
DNA sequence of the simian varicella virus genome. Virology 284,
123–130.
Hickey, W. F., Hsu, B. L., and Kimura, H. (1991). T-lymphocyte entry into
the central nervous system. J. Neurosci. Res. 28, 254–260.
Ito, Y., Kimura, H., Hara, S., Kido, S., Ozaki, T., Nishiyama, Y., and
Morishima, T. (2001). Investigation of varicella-zoster virus DNA in
lymphocyte subpopulations by quantitative PCR assay. Microbiol.
Immunol. 45, 267–269.
Koropchak, C. M., Solem, S. M., Diaz, P. S., and Arvin, A. M. (1989).
Investigation of varicella-zoster virus infection of lymphocytes by in
situ hybridization. J. Virol. 63, 2392–2395.
Ljungman, P., Lonnqvist, B., Gahrton, G., Ringden, O., Sundqvist, V. A.,
and Wahren, B. (1986). Clinical and subclinical reactivations of vari-
cella-zoster virus in immunocompromised patients. J. Infect. Dis. 153,
840–847.
Mahalingam, R., Clarke, P., Wellish, M., Dueland, A. N., Soike, K. F.,
Gilden, D. H., and Cohrs, R. (1992). Prevalence and distribution of
latent simian varicella virus DNA in monkey ganglia. Virology 188,
193–197.
Mahalingam, R., Lasher, R., Wellish, M., Cohrs, R. J., and Gilden, D. H.
(1998). Localization of varicella-zoster virus gene 21 protein in virus-
infected cells in culture. J. Virol. 72, 6832–6837.
Mahalingam, R., Smith, D., Wellish, M., Wolf, W., Dueland, A. N., Cohrs,
R., Soike, K., and Gilden, D. (1991). Simian varicella virus DNA in
dorsal root ganglia. Proc. Natl. Acad. Sci. USA 88, 2750–2752.
Mahalingam, R., Wellish, M., Brucklier, J., and Gilden, D. H. (1995).
Persistence of varicella-zoster virus DNA in elderly patients with
postherpetic neuralgia. J. Neurovirol. 1, 130–133.
Mahalingam, R., Wellish, M., Soike, K., White, T., Kleinschmidt-DeMas-
ters, B. K., and Gilden, D. H. (2001). Simian varicella virus infects
ganglia before rash in experimentally infected monkeys. Virology
279, 339–342.
Mahalingam, R., Wellish, M., Wolf, W., Dueland, A. N., Cohrs, R., Vafai, A.,
and Gilden, D. (1990). Latent varicella-zoster viral DNA in human
trigeminal and thoracic ganglia. N. Engl. J. Med. 323, 627–631.
Mainka, C., Fuss, B., Geiger, H., Hofelmayr, H., and Wolff, M. H. (1998).
Characterization of viremia at different stages of varicella-zoster
virus infection. J. Med. Virol. 56, 91–98.
Miller, S. A., Dykes, D. D., and Polesky, H. F. (1988). A simple salting out
procedure for extracting DNA from human nucleated cells. Nucleic
Acids Res. 16, 1215.
Ozaki, T., Kajita, Y., Asano, Y., Aono, T., and Yamanishi, K. (1994).
Detection of varicella-zoster virus DNA in blood of children with
varicella. J. Med. Virol. 44, 263–265.
Padovan, D., and Cantrell, C. A. (1986). Varicella-like herpesvirus infec-
tions of nonhuman primates. Lab. Anim. Sci. 36, 7–13.
Soike, K. F., Cantrell, C., and Gerone, P. J. (1986). Activity of 1-(2-deoxy-
2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil against simian vari-
cella virus infections in African green monkeys. Antimicrob. Agents
Chemother. 29, 20–25.
Soike, K. F., Rangan, S. R., and Gerone, P. J. (1984). Viral disease models
in primates. Adv. Vet. Sci. Comp. Med. 28, 151–199.
Soong, W., Schultz, J. C., Patera, A. C., Sommer, M. H., and Cohen, J. I.
(2000). Infection of human T lymphocytes with varicella-zoster virus:
An analysis with viral mutants and clinical isolates. J. Virol. 74,
1864–1870.
Vafai, A., Wellish, M., and Gilden, D. H. (1988). Expression of varicella-
zoster virus in blood mononuclear cells of patients with postherpetic
neuralgia. Proc. Natl. Acad. Sci. USA 85, 2767–2770.
Vonsover, A., Leventon-Kriss, S., Langer, A., Smetana, Z., Zaizov, R.,
Potaznick, D., Cohen, I. J., and Gotlieb-Stematsky, T. (1987). Detection
of varicella-zoster virus in lymphocytes by DNA hybridization. J. Med.
Virol. 21, 57–66.
Wenner, H. A., Abel, D., Barrick, S., and Seshumurty, P. (1977). Clinical
and pathogenetic studies of Medical Lake macaque virus infections
in cynomolgus monkeys (simian varicella). J. Infect. Dis. 135, 611–
622.
White, T. M., Mahalingam, R., Traina-Dorge, V., and Gilden, D. H. (2002).
Simian varicella virus DNA is present and transcribed months after
experimental infection of adult African green monkeys. J. Neurovirol.
8, 191–205.
Wilson, A., Sharp, M., Koropchak, C. M., Ting, S. F., and Arvin, A. M.
(1992). Subclinical varicella-zoster virus viremia, herpes zoster, and T
lymphocyte immunity to varicella-zoster viral antigens after bone
marrow transplantation. J. Infect. Dis. 165, 119–126.
Zerboni, L., Sommer, M., Ware, C. F., and Arvin, A. M. (2000). Varicella-
zoster virus infection of a human CD4-positive T-cell line. Virology
270, 278–285.
198 WHITE ET AL.
